MedinCell will publish its annual results (April 2022-March 2023) on June 26, 2023
05 Junio 2023 - 12:04PM
Business Wire
Regulatory News:
Due to operational imperatives, the publication of annual
results for the year ending March 31, 2023, originally scheduled
for June 13th, has been postponed to June 26th, 2023. On the same
day, MedinCell (Paris:MEDCL) will hold a videoconference for its
shareholders and the financial community.
About MedinCell
MedinCell is an innovative pharmaceutical company developing a
portfolio of long-acting injectable products in various therapeutic
areas - from development to commercialization - by combining its
proprietary BEPO® technology (licensed to Teva under the name
SteadyTeq™) with active ingredients already known and marketed.
Through the controlled and extended release of the active
pharmaceutical ingredient, MedinCell makes medical treatments more
efficient, particularly thanks to improved compliance and to a
significant reduction in the quantity of medication required.
MedinCell's proprietary BEPO technology makes it possible to
control the delivery of a drug at a therapeutic dose for several
days, weeks or months, from the subcutaneous or local injection of
a simple, fully bioresorbable deposit just a few millimeters in
size. The first treatment based on BEPO technology for the
treatment of schizophrenia was approved by the FDA in April 2023
and is now commercialized in the United States by Teva under the
name UZEDY™. MedinCell collaborates with leading pharmaceutical
companies and foundations to improve global health through new
therapeutic options. Based in Montpellier, MedinCell currently
employs over 140 people representing more than 25 different
nationalities. www.medincell.com UZEDY™ and SteadyTeq™ are
trademarks of Teva Pharmaceuticals
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230605005721/en/
MedinCell David Heuzé Head of Communications
david.heuze@medincell.com +33 (0)6 83 25 21 86 NewCap Alban
Dufumier / Louis-Victor Delouvrier Investor Relations
medincell@newcap.eu +33 (0)1 44 71 94 94 NewCap Nicolas Merigeau
Media Relations medincell@newcap.eu +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Medincell (EU:MEDCL)
Gráfica de Acción Histórica
De May 2023 a May 2024